Key Highlights
- Philippe Sauvage brings over 20 years of leadership in finance and operations within global biopharma and healthcare.
- Formerly Global Head of Operations and Access at Sanofi, overseeing market access and commercialization strategies.
- Led financial operations for Sanofi-Genzyme and Sanofi North America in a $14 billion region.
- Will support Nuvation Bio’s transition to a commercial-stage company by 2025.
Source: Business Wire
Notable Quotes
- “We are excited to welcome Philippe to Nuvation Bio at such an important stage of our evolution.” — David Hung, M.D., Founder, President, and CEO at Nuvation Bio
- “I am thrilled to join Nuvation Bio as the team prepares for the potential commercialization of taletrectinib.” — Philippe Sauvage, Chief Financial Officer at Nuvation Bio
SoHC's Take
Nuvation Bio’s strategic appointment of Philippe Sauvage as CFO is a pivotal move as the company gears up for the commercialization of taletrectinib and further advancement of its oncology pipeline. With extensive experience in global finance, operations, and market access across the U.S., European, and Asian markets, Sauvage is well-positioned to guide Nuvation Bio through its next phase of growth. His background in both the public and private healthcare sectors adds a valuable dimension as Nuvation Bio prepares to meet the complex financial and operational demands of bringing innovative cancer treatments to market.
